Prevalence of Potentially Pathogenic Germline Variants Among Adult Patients in the Philippines With Solid Malignancies Who Underwent Tumor Genomic Profiling
- 1 June 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400019
Abstract
PURPOSE: In high-income countries, 2%-10% of tumor genomic profiling (TGP) reports reveal incidental pathogenic germline variants. A third of these patients would not qualify for genetic testing on the basis of current guidelines. Our study determined the prevalence of potentially pathogenic germline variants (PPGVs) in TGP results of adult patients with solid malignancies in the Philippines. METHODS: Annotated reports of patients with solid cancers who underwent TGP using FoundationOne or FoundationOne Heme between January 2021 and July 2023 were reviewed. PPGV criteria include having a variant allele frequency of >30% and were categorized as (1) high penetrance gene (HP), founder variant (FV), or variant associated with clinical presentation (VA). Pathogenicity was crosschecked through the ClinVar database. RESULTS: Of 446 patients, 13 PPGV variants were found in 50 (11.2%) patients at a median age of 60.5 years. Of them, 28 (56%) had HP ( BRCA1, BRCA2, MSH2, MSH6, MLH1, RAD51C, RAD51D), 25 (50%) patients had VA ( APC, SMAD4, CDH1, CDKN2A, PTEN), and two patients with lung cancer had a FV ( EGFR p.Thr790Met). Six patients had more than one PPGV. PPGVs were primarily found in patients with colorectal (42% of 50 patients with PPGVs), breast (16%), ovarian (6%), and lung (6%) cancer ( P < .001). HP genes were mostly found in female patients (71.4%; P = .03). CONCLUSION: With a PPGV prevalence of 11% in this study, it is important to recognize PPGVs as it can prompt genetic counseling and confirmatory germline testing.Keywords
This publication has 22 references indexed in Scilit:
- Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testingnpj Precision Oncology, 2023
- P28-10 Survival difference between EGFR exon 19 deletion and exon 21 mutation in advanced non-small cell lung cancer patientsAnnals of Oncology, 2022
- Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing GuidelinesJAMA Network Open, 2022
- A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective studyThe Lancet Oncology, 2021
- Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeJAMA Oncology, 2021
- Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non–Hodgkin LymphomaJAMA Oncology, 2019
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline TestingJAMA, 2017
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolAnnals of Oncology, 2016
- Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromesActa Pharmacologica Sinica, 2015
- Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarianCancer, 2014